State Drug Administration: to promote the development and marketing of the new coronal pneumonia vaccine.

On July 16, the Party Group of the State Drug Administration held a meeting to hear a report on the implementation of the key work of the Party Group of the State Drug Administration in the first half of the year, and to study the deployment of the second half of the year, according to the website of the State Drug Administration.
meeting pointed out that the prevention and control of the epidemic should be done carefully, the emergency approval of drug prevention and control of the epidemic should be done in a solid and solid, and the research and development of the new crown pneumonia vaccine should be launched, and the voluntary service of pharmaceutical enterprises should resume production.
meeting pointed out that in the first half of this year, the State Drug Administration earnestly implemented the "four most stringent" requirements, strengthen the party building leadership, one hand to catch the epidemic prevention and control, one hand grasp daily supervision, strong and orderly promotion of various work, achieved remarkable results.
service to ensure the effectiveness of epidemic prevention and control work outstanding, testing reagents, medical protective clothing, medical masks and other market protection is strong, a number of new coronavirus vaccines, epidemic prevention and control drugs to carry out clinical trials.
the overall supervision of drug, drug safety situation remained stable, the pace of new drug market accelerated, drug regulatory standards system more perfect.
actively cooperate with the central inspection, resolutely implement the political responsibility of fighting out poverty, and the Party's leadership and party building have been significantly strengthened.
stressed that to do a good job in the second half of the year, we should effectively enhance the "four consciousness", firm "four self-confidence", achieve "two maintenance", earnestly implement the Party Central Committee, the State Council on epidemic prevention and control, do a good job of "six stability", implement the "six guarantees" and other decision-making deployment, adhere to the two-handed grasp, two hands hard, resolutely win the epidemic prevention and control of the people's war, overall war, resistance, and strive to complete the year's objectives and efforts to achieve the modernization of the drug regulatory system and the ability to control the epidemic.
first, we should deeply promote the overall strict governance of the Party, further strengthen the construction of political organs, earnestly grasp the central inspection and rectification, strengthen the construction of the ranks of pharmaceutical supervisors, and promote the whole dare not rot, not corrupt, do not want to rot.
second to do a good job in the prevention and control of the epidemic, a solid job of emergency approval of epidemic prevention and control drugs, to promote the new crown pneumonia vaccine research and development market, take the initiative to serve pharmaceutical enterprises to resume production.
third, we should firmly adhere to the bottom line of drug safety, improve the long-term mechanism for the detection of hidden risks, reform and improve the system of vaccine supervision, strengthen the supervision of high-risk products and key varieties, and promote the implementation of the responsibility of all parties to drug safety.
fourth, we should deepen the reform of the review and approval system, establish and improve the mechanism for accelerating the listing of pharmaceuticals, support the innovation and development of Chinese medicine inheritance, coordinate and deepen the reform of the review and approval system of medical devices and cosmetics, and promote the high-quality development of the pharmaceutical industry.
Fifth, we should strengthen the modernization of regulatory capacity, carefully prepare the "14th Five-Year Plan" for drug safety and high-quality development, improve the standard system of drug regulations, vigorously develop intelligent supervision and regulatory science, strengthen the capacity of drug supervision and support, and lay a solid foundation for the successful conclusion of the 13th Five-Year Plan and the good start of the 14th Five-Year Plan.
.